For patients who received a letter on improperly disclosed information by a claims processing vendor, read more.
Hepatorenal Syndrome Type 1 Treatment Study
An investigational drug is being studied that may help slow down or reverse kidney failure (hepatorenal syndrome [HRS] type 1) in patients with chronic liver disease. Nationwide, 300 patients will be recruited for this study. At Rush University Medical Center we expect to recruit approximately 10 patients. The treatment will be assigned randomly.
In order to participate you must meet the following criteria:
- Are at least 18 years of age.
- Are an adult with cirrhosis (scarring of the liver), ascites (fluid in the abdomen), and a diagnosis of HRS type 1.
- Have rapidly progressive reduction in renal function.
- Have confirmation that albumin was given.
- Pass certain screening tests.
You will be excluded from the study if any of the following criteria apply to you:
- Have severe cardiovascular disease.
- Have shock or sepsis.
- Have a paracentesis > 4L 2 days before.
- Have (TIPS) within 30 days
This is a partial list of inclusion and exclusion criteria.